Thirdly, this study excluded patients with prior exposure to PARP inhibitors, who would likely constitute considerable proportions of PROC patients given the widespread front-line application of PARP inhibitors in ovarian cancer. This evidence concerns the gene PARP1 and ovarian cancer.